Case Investigations

Apyx Medical

April 24, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Apyx Medical Corporation (“Apyx Medical” or the “Company”) (NASDAQ: APYX), a company developing J-Plasma technology, a plasma-based surgical product for cutting, coagulation and ablation of soft tissue.  A complaint has been filed in the United States District Court for the Middle District of Florida against the Company and its Chief Executive Officer.  Investors that acquired Apyx Medical securities between August 1, 2018 and April 1, 2019, inclusive (the “Class Period”), may be affected.

BrightView Holdings, Inc.

April 24, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of BrightView Holdings, Inc. (“BrightView” or the “Company”) (NYSE: BV).

Lyft, Inc.

April 18, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Lyft, Inc. (“Lyft” or “Company”) (NASDAQ: LYFT).

Fusion Connect, Inc.

April 18, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Fusion Connect, Inc. (“Fusion Connect” or the “Company”) (NASDAQ: FSNN).  A complaint has been filed in the United States District Court for the Southern District of New York against the Company and certain executives.  Investors who purchased Fusion Connect shares between August 14, 2018 and April 2, 2019, inclusive (the “Class Period”), may be affected.

Indivior PLC

April 17, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Invidior PLC (OTC: INVVY).

Aerojet Rocketdyne Holdings, Inc.

April 17, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Aerojet Rocketdyne Holdings, Inc. (“Aerojet Rocketdyne” or the “Company”) (NYSE: AJRD).

Amyris, Inc.

April 15, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Amyris, Inc. (NASDAQ: AMRS), an industrial biotechnology company that manufactures and sells natural, sustainably-sourced products in health and wellness, clean beauty, and flavor and fragrance markets.  Investors who purchased Amyris securities may be affected.

Zogenix, Inc.

April 15, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing rare disease therapies.  Investors who purchased Zogenix securities between February 6, 2019 and April 8, 2019, inclusive (the “Class Period”), may be affected.  A complaint has been filed in the United States District Court for the Northern District of California against the Company, its Chief Executive Officer, and its Chief Financial Officer.

KushCo Holdings, Inc.

April 10, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of KushCo Holdings, Inc. (OTC: KSHB).

Healthcare Services Group, Inc.

April 2, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Healthcare Services Group, Inc. (“Healthcare Services” or the “Company”) (NASDAQ: HCSG).  Investors who purchased Healthcare Services’ securities between April 11, 2017 and March 4, 2019, inclusive (the “Class Period”), may be affected.  A complaint has been filed in the United States District Court for the Eastern District of Pennsylvania against the Company and its Chief Executive Officer and President, Theodore Wahl (“Wahl”).

American Renal Associates Holdings, Inc.

April 2, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of American Renal Associates Holdings, Inc. (“American Renal” or the “Company”) (NYSE: ARA), a company that through its subsidiaries owns and operates kidney dialysis centers.  A complaint has been filed in the United States District Court for the District of New Jersey against the Company and certain executives.  Investors that purchased American Renal securities between August 10, 2016 and March 27, 2019, inclusive (the “Class Period”), may be affected.

Care.com, Inc.

April 2, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Care.com, Inc. (“Care.com” or the “Company”) (NYSE: CRCM), a company that operates an online service for babysitters and other caregivers.

Everquote, Inc.

March 26, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of EverQuote, Inc. (“EverQuote” or the “Company”) (NASDAQ: EVER), an online lead generation company, specializing primarily in leads for auto insurance.

The Boeing Company

March 18, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of The Boeing Company (“Boeing” or the “Company”) (NYSE: BA).  Investors who purchased Boeing securities may be affected.

U.S. Xpress Enterprises, Inc.

March 18, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of U.S. Xpress Enterprises, Inc. (“U.S. Xpress” or the “Company”) (NYSE: USX).  An action has been filed on behalf of investors who purchased or otherwise acquired U.S. Xpress common stock pursuant and/or traceable to the Company’s June 2018 initial public offering (the “IPO”).

United Microelectronics Corporation

March 18, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of United Microelectronics Corporation (“UMC” or the “Company”) (NYSE: UMC).  Investors who purchased or otherwise acquired UMC’s American Depositary Shares (ADSs) or other UMC securities between October 28, 2015 and November 1, 2018, inclusive (the “Class Period”), may be affected.  A complaint has been filed in the United States District Court for the Southern District of New York against the Company and certain executives.

Eventbrite, Inc.

March 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Eventbrite, Inc. (“Eventbrite” or the “Company”) (NYSE: EB).  Investors who purchased Eventbrite securities may be affected.

American Renal Associates Holdings, Inc.

March 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of American Renal Associates Holdings, Inc. (“American Renal” or the “Company”) (NYSE: ARA), a company that through its subsidiaries owns and operates kidney dialysis centers.  Investors that purchased American Renal securities may be affected.

CenturyLink, Inc.

March 11, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CenturyLink, Inc. (“CenturyLink” or the “Company”) (NYSE: CTL).  Investors who purchased CenturyLink securities between May 10, 2018 and March 4, 2019, inclusive (the “Class Period”), may be affected.  A complaint has been filed in the United States District Court for the Central District of California against the Company and certain executives (the “Action”).

Healthcare Services Group, Inc.

March 6, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Healthcare Services Group, Inc. (Nasdaq: HCSG).

Nio Inc.

March 6, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Chinese electric carmaker Nio Inc. (NYSE: NIO).

FTS International, Inc.

March 4, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of FTS International, Inc. (“FTS” or the “Company”) (NYSE: FTSI), purportedly one of the largest providers of hydraulic fracturing services in North America.  A complaint has been filed against the Company, certain officers and directors, and the underwriters of the Company’s February 2018 initial public offering (“IPO”) alleging that the Registration Statement and other offering documents for the IPO were materially false and misleading.

Syneos Health, Inc.

February 28, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Syneos Health, Inc. (Nasdaq: SYNH).

Stamps.com

February 26, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Stamps.com Inc. (“Stamps.com” or the “Company”) (NASDAQ: STMP).  Investors who purchased Stamps.com securities may be affected.

Diplomat Pharmacy, Inc.

February 22, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Diplomat Pharmacy, Inc. (“Diplomat Pharmacy” or the “Company”) (NYSE: DPLO), a specialty pharmacy company. Investors who purchased or otherwise acquired Diplomat Pharmacy’s publicly traded securities may be affected.

Health Insurance Innovations, Inc.

February 21, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Health Insurance Innovations, Inc. (“Health Insurance Innovations”, “HIIQ” or the “Company”) (NASDAQ: HIIQ), a company that purportedly distributes individual and family health insurance plans, including short-term medical insurance plans, and guaranteed-issue and underwritten health benefit insurance plans.  Investors who purchased Health Insurance Innovations securities between February 28, 2018 and November 27, 2018, inclusive (the “Class Period”), may be affected.  A complaint has been filed in the United States District Court for Middle District of Florida against the Company and certain executives (the “Action”).

Synergy Pharmaceuticals Inc.

February 20, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Synergy Pharmaceuticals Inc. (“Synergy” or the “Company”) (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of therapies to treat Gastro-Intestinal disorders and diseases.  Investors who purchased Synergy securities between September 7, 2017 and October 25, 2018, inclusive (the “Class Period”), may be affected.  A complaint has been filed in the United States District Court for the Eastern District of New York against certain Synergy executives.

CPI Aerostructures Inc.

February 19, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of CPI Aerostructures Inc. (NYSE: CVU).

Mattel, Inc.

February 19, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Mattel, Inc. (Nasdaq: MAT).  Purchasers of Mattel securities between February 8 and 15, 2019 may be affected.

Uxin Limited

February 14, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Uxin Limited (“Uxin” or the “Company”) (NASDAQ: UXIN), a Chinese company that operates an e-commerce platform for buying and selling cars.  A complaint has been filed in the United States District Court for the Eastern District of New York against the Company, certain executives and the underwriters of Uxin’s June 2018 initial public offering (“IPO”) on behalf of investors who purchased or otherwise acquired Uxin’s publicly traded securities pursuant to and/or traceable to the Company’s IPO.